[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2)∶69-90 [2] Mayne ST, Cartmel B, Kirsh V, et al. Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx [J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(12)∶3368-3374 [3] Petersen PE. Oral cancer prevention and control-the approach of the World Health Organization [J]. Oral Oncol, 2009, 45(4-5)∶454-460 [4] Hanken H, Grobe A, Cachovan G, et al. CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas [J]. Clin Oral Investig, 2013 [5] da Costa BR, Cevallos M, Altman DG, et al. Uses and misuses of the STROBE statement: bibliographic study [J]. BMJ Open, 2011, 1(1)∶e000048 [6] Jackson D, Baker R and Bowden J. A sensitivity analysis framework for the treatment effect measure used in the meta-analysis of comparative binary data from randomised controlled trials [J]. Stat Med, 2013, 32(6)∶931-940 [7] Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis [J]. JAMA, 2006, 295(6)∶676-680 [8] Zintzaras E, Chatzoulis DZ, Karabatsas CH, et al. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis [J]. J Hum Genet, 2005, 50(6)∶267-275 [9] Tsai MH, Tsai CW, Tsou YA, et al. Significant association of cyclin D1 single nucleotide polymorphisms with oral cancer in taiwan [J]. Anticancer Res, 2011, 31(1)∶227-231 [10] Liu W, Zhu E, Wang R, et al. Cyclin D1 gene polymorphism, A870G, is associated with an increased risk of salivary gland tumors in the Chinese population [J]. Cancer Epidemiol, 2011, 35(4)∶e12-17 [11] Yadav BK, Kaur J, Srivastava A, et al. Effect of polymorphisms in XRCC1, CCND1 and GSTM1 and tobacco exposure as risk modifier for oral leukoplakia [J]. Int J Biol Markers, 2009, 24(2)∶90-98 [12] Ye Y, Lippman SM, Lee JJ, et al. Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions [J]. Cancer, 2008, 113(9)∶2488-2495 [13] Gomes CC, Drummond SN, Guimaraes AL, et al. P21/ WAF1 and cyclin D1 variants and oral squamous cell carcinoma [J]. J Oral Pathol Med, 2008, 37(3)∶151-156 [14] Sathyan KM, Nalinakumari KR, Abraham T, et al. Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility [J]. Oral Oncol, 2006, 42(6)∶607-613 [15] Huang M, Spitz MR, Gu J, et al. Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions [J]. Carcinogenesis, 2006, 27(10)∶2034-2037 [16] Jirawatnotai S, Hu Y, Livingston DM, et al. Proteomic identification of a direct role for cyclin d1 in DNA damage repair [J]. Cancer Res, 2012, 72(17)∶4289-4293 [17] Lu C, Dong J, Ma H, et al. CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis [J]. Breast Cancer Res Treat, 2009, 116(3)∶571-575 |